Details

Autor(en) / Beteiligte

• Saunders, Kevin O
• Lee, Esther
• Parks, Robert
• Martinez, David R
• Li, Dapeng
• Chen, Haiyan
• Edwards, Robert J
• Gobeil, Sophie
• Barr, Maggie
• Mansouri, Katayoun
• Alam, S Munir
• Sutherland, Laura L
• Cai, Fangping
• Sanzone, Aja M
• Berry, Madison
• Manne, Kartik
• Bock, Kevin W
• Minai, Mahnaz
• Nagata, Bianca M
• Kapingidza, Anyway B
• Azoitei, Mihai
• Tse, Longping V
• Scobey, Trevor D
• Spreng, Rachel L
• Rountree, R Wes
• DeMarco, C Todd
• Denny, Thomas N
• Woods, Christopher W
• Petzold, Elizabeth W
• Tang, Juanjie
• Oguin, 3rd, Thomas H
• Sempowski, Gregory D
• Gagne, Matthew
• Douek, Daniel C
• Tomai, Mark A
• Fox, Christopher B
• Seder, Robert
• Wiehe, Kevin
• Weissman, Drew
• Pardi, Norbert
• Golding, Hana
• Khurana, Surender
• Acharya, Priyamvada
• Andersen, Hanne
• Lewis, Mark G
• Moore, Ian N
• Montefiori, David C
• Baric, Ralph S
• Haynes, Barton F

Titel

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Ist Teil von

• Nature (London), 2021-06, Vol.594 (7864), p.553-559

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Betacoronaviruses caused the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 (SARS-CoV-2) . Vaccines that elicit protective immunity against SARS-CoV-2 and betacoronaviruses that circulate in animals have the potential to prevent future pandemics. Here we show that the immunization of macaques with nanoparticles conjugated with the receptor-binding domain of SARS-CoV-2, and adjuvanted with 3M-052 and alum, elicits cross-neutralizing antibody responses against bat coronaviruses, SARS-CoV and SARS-CoV-2 (including the B.1.1.7, P.1 and B.1.351 variants). Vaccination of macaques with these nanoparticles resulted in a 50% inhibitory reciprocal serum dilution (ID ) neutralization titre of 47,216 (geometric mean) for SARS-CoV-2, as well as in protection against SARS-CoV-2 in the upper and lower respiratory tracts. Nucleoside-modified mRNAs that encode a stabilized transmembrane spike or monomeric receptor-binding domain also induced cross-neutralizing antibody responses against SARS-CoV and bat coronaviruses, albeit at lower titres than achieved with the nanoparticles. These results demonstrate that current mRNA-based vaccines may provide some protection from future outbreaks of zoonotic betacoronaviruses, and provide a multimeric protein platform for the further development of vaccines against multiple (or all) betacoronaviruses.